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1. Introduction 
Tuberculosis (TB) is a life-threatening, infectious disease caused by the bacteria 
Mycobacterium tuberculosis. The disease has plagued human beings for many centuries as 
signs of tubercular damage have been found in Egyptian mummies and bones dating back 
at least 5,000 years ago [1]. Today, despite advances in diagnosis and treatment, TB is still a 
global pandemic, fueled by the spread of the Human Immunodeficiency Virus (HIV), the 
Acquired Immunodeficiency Syndrome (AIDS), poverty and a lack of proper health services 
in many developing countries [2]. As a developing nation, many of the Caribbean countries 
face serious challenges in the diagnosis, treatment, care and management of patients with 
TB. Some of these challenges include TB/HIV co-infection, drug resistance, inadequate 
laboratory services, growth of inequity stemming from rising poverty and the presence of 
weak health systems in many countries [3]. A major challenge that affects the Caribbean is 
the lack of proper facilities for laboratory diagnosis of TB; and there is a dire shortage of 
laboratory facilities and capability for culture and drug susceptibility testing. Because of 
this, many cases of TB with low bacillary load may be missed by smear microscopy if 
culture is not routinely performed. This is even more so in HIV/AIDS patients where smear 
microscopy may be negative due to the small numbers of bacilli being produced as a result 
of reduced pulmonary cavity formation [4].  
Weak laboratory service is one of the major obstacles to reducing the global burden of TB. 
The clinical mycobacteriology laboratory plays a major role in the prevention strategies and 
control measures of TB [5]. A wide spectrum of laboratory techniques has been developed to 
confirm the diagnosis of active and latent TB infection. No single laboratory test method is 
perfect, and unfortunately, some of the methods of diagnosis on which clinicians still rely on 
were developed more than a century ago. 
It was based on these challenges that the aims of this study were conceived - to compare the 
available screening and investigative methods for detection of latent TB in Trinidad and 
Tobago; and also to evaluate methods for detection of drug resistance to Mycobacterium 
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tuberculosis isolates recovered from clinical and cultured specimens from several Caribbean 
countries.  
2. Materials and methods 
Study setting and Site: The overall study design and methods have been described 
previously [6, 7]. Briefly, this prospective observational cross sectional population and 
laboratory based study was carried out at the Mycobacteriology laboratory at the Caribbean 
Epidemiology Centre (CAREC) in Trinidad and Tobago. The materials used for the study 
included individuals and clinical specimens from patients managed for TB infection in 
Trinidad and Tobago collected over a twelve month period as well as convenient clinical 
specimens and M. tuberculosis isolates from several countries in the Caribbean that were 
referred to CAREC for culture, identification and drug susceptibility testing over a twenty 
four month period.  
Specimen collection: The specimens used included sputum and other clinical specimens 
from several Caribbean countries including Antigua, Belize, Dominica, Jamaica, Montserrat, 
St. Kitts, Nevis, St. Lucia, St. Vincent and the Grenadines, Trinidad and Tobago and Turks 
and Caicos Islands. While sputum and clinical specimens were referred from countries that 
did not perform culture or was not performing culture for TB during the study, cultures on 
Lowestein Jensen (LJ) slants were referred from countries that had the capability to perform 
culture for mycobacteria but were unable to perform identification and drug susceptibility 
testing. These countries included The Bahamas, Barbados, Trinidad and Tobago, Suriname 
and Guyana. For specimens coming from Trinidad and Tobago, both clinical specimens and 
cultures on LJ were included in the study. Diagnosis of latent TB infection was performed 
using the Quantiferon Gold Assay. For this test blood samples were collected in heparinized 
tubes. Individuals for this assay included contacts of confirmed tuberculosis patients, health 
care workers from the Caura Chest Hospital and the Chest Clinic at the Eric Williams 
Medical Sciences Complex, inmates of the maximum security prison (where a case of TB 
was identified) and HIV positive patients attending routine care and treatment clinic. 
All specimens referred to CAREC over a two year period (September 2006 – August 2008) 
from the CAREC Member Countries except Trinidad and Tobago were included in the 
study. Only specimens from Trinidad and Tobago referred to CAREC over a one year 
period (September 2006 to October 2007) were included in the study. Clinical specimens 
were collected from hospitalized patients, chest clinics and sometimes from patients 
attending the offices of their private physicians and sent to the hospital laboratory or public 
health laboratory in each country for acid fast bacilli. For culture and drug susceptibility 
testing (DST), a portion of the specimen was referred, while for laboratories that are able to 
culture for mycobacteria, clinical specimens were processed using the N-acetyl-L-cysteine-
sodium hydroxide (NALC-NaOH) method, inoculated and incubated until visible growth 
was seen on the LJ slants. Slants showing positive growth were then referred for 
identification and DST. Patients from Trinidad and Tobago in addition to giving blood 
specimens placed in heparin and transported at room temperature to the laboratory for 
detection of latent TB also had tuberculin skin tests (Mantoux test) administered on their 
forearm. Results of the reaction were was read after 72 hours.  
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Inclusion and exclusion criteria: (a) Only specimens showing positive growth on LJ or 
BACTEC 460 TB system were further analysed. (b) Repeat specimens or culture were not 
included. (c) Specimens without basic demographic data were excluded. (d) Cultures that 
showed growth of contaminating organisms were also not included in the study. 
Data collection: For specimens originating from Trinidad & Tobago, a standardized 
questionnaire was used to obtain additional information of the test subjects. The 
questionnaire was divided into several sections including demographics, clinical 
information, medical history, laboratory investigation, radiographic findings, risk factors 
and treatment. Several methods were used to collate data, including going through the 
patient’s file at the hospital and speaking to the County and the Public Health Nurses. 
Information (usually age, gender, type of specimen, HIV status and nationality) of 
specimens from other countries was taken from the patient’s form that accompanied the 
specimens when they were received at the laboratory for culture, identification and DST. 
Information obtained was then entered into Excel spreadsheet for analysis. 
Digestion and Decontamination of the specimens: All clinical specimens were processed in 
a Biological Safety Cabinet (BSC) using the NALC-NaOH method as previously described in 
literature [8]. Specimens on LJ slants were also processed in a BSC observing all safety 
precautions that are applicable when working with live tuberculosis cultures as has been 
described [9]. From the LJ slants colonies of growth were removed with a sterile disposable 
loop and placed in tubes containing glass beads and 0.5ml sterile distilled water. The tubes 
were vortexed for approximately 10 seconds to break up the large clumps of mycobacteria 
and then left undisturbed for 5-10 minutes. Following this, 0.1 ml portions of the 
supernatant were used to inoculate into BACTEC 12B vials only. 
Processing of blood sample for latent TB detection: Blood specimens in heparin tubes were 
incubated overnight with antigens according to the manufacturer’s (Cellestis Inc., USA) 
instructions. To do this the blood was mixed at least 20 times by gently inverting the tube, 
then in a 24 well culture plate 1.0ml of blood was placed in each of 4 wells. To each well 3 
drops of the respective reagent was added; saline (NIL), early secretory antigen target-6 
(ESAT-6), culture filtrate protein-10 (CFP-10) and phytohemaglutinin (Mitogen control), 
mixed thoroughly into the blood using a plate shaker for 1-2 minutes and then incubated 
overnight at 37oC. After overnight incubation, the plasma was removed from each well, 
placed in labeled tubes and stored at 4oC after which the enzyme linked immunosorbent 
assay (ELISA) test for the detection of IFN-Ǆ was performed. 
Culture of clinical specimens: Clinical specimens were cultured using two types of media, the 
LJ media and 12B media using the BACTEC 460 TB system (Becton Dickenson). For this 0.1 ml 
of sediments were added aseptically into each of these two media using a tuberculin syringe 
and needle. Supernatant from LJ cultures were only inoculated on 12B media as above. Both LJ 
slants and 12B vials were incubated at 37oC. 12B vials were read twice weekly for the first 2 
weeks and then once a week for the next 6 weeks for the presence of growth while LJ slants 
were read weekly for up to 8 weeks. 12B cultures showing positive growth (between 50 to 100 
growth units) or LJ slants showing colonies of mycobacteria were removed and identified 
using the NAP (p-nitro-ǂ-acetylamino-ǃ-hydroxyl-propiophenone) test. Cultures that showed 
growth of contaminating organisms were discarded. The supernatant was reprocessed and 
reinoculated. If the cultures were still contaminated, they were discarded. 
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Identification of mycobacteria using the NAP test: When mycobacterial growth was 
detected from either the 12B growth media or the LJ slants, each isolate was further 
identified using the NAP test. This test was performed by adding 1.0 ml of positive culture 
media to a vial containing p-nitro-ǂ-acetylamino ǃ-hydroxyl-propiophenone. This vial 
together with the original culture vial was incubated at 370C and read daily for 4 
consecutive days. The culture was identified as M. tuberculosis Complex (MTBC) if the tube 
containing NAP did not allow growth of the mycobacteria while the original tube continued 
to grow. If growth was detected in both tubes, then the culture was identified as non-
tuberculous mycobacteria (NTM); and these were further identified to species level using 
the Common Mycobacteria (CM) genotyping line probe assay from Hain Lifesciences 
(Germany). For quality control, a Clinical and Laboratory Standards Institute (CLSI) strain 
of M. tuberculosis, H37Rv was tested along with test specimens each week and for each new 
lot number of reagents that was used. 
Drug Susceptibility Testing using BACTEC 460 TB System: Drug susceptibility tests 
(DSTs) using the BACTEC 460 TB system was performed on all isolates that belonged to the 
MTBC group. Only DST to 4 first line drugs and their concentrations - Streptomycin 
(2.0mg/L), Isoniazid (0.1mg/L), Rifampicin (2.0mg/L) and Ethambutol (2.5mg/L) were 
used for the study. For DSTs, 0.1 ml of broth from each positive specimen was inoculated to 
12B vials containing fixed concentrations of the antibiotics listed above. A control vial 
without antibiotics was also inoculated with a 1:100 dilution of the respective growth media. 
All vials were incubated at 37oC and read daily in the BACTEC 460 machine until the 
control tube read 30 growth units. 
The result of each test was determined as resistant if they were above or susceptible if below 
of the control GI reading. For quality control, once a month and when new antibiotics were 
prepared, cultures with known resistance patterns were tested along with the test 
specimens.  
Identification of Mycobacteria using Hain Genotyping Assay: This procedure consisted of 
the following summarized steps: (a) DNA extraction from mycobacterial culture;  (b) 
Preparation of Master Mix for PCR procedure; (c) Amplification Procedure; (d) 
Hybridization and Detection and; (e) Interpretation of results 
DNA extraction: DNA extraction was performed using mycobacteria from liquid cultures 
(i.e. from positive 12B BACTEC culture vials). DNA extraction was performed when there 
was heavy growth of mycobacteria (when the liquid culture read at least 900 growth 
units). In a BSC 1.0ml of the culture was removed from the vial with a tuberculin needle 
and syringe and placed in a 2.5ml micro-centrifuge tube. The tube was then closed and 
centrifuged in a micro-centrifuge for 15 minutes at 13,000 r.p.ms. After centrifugation the 
supernatant was removed and the sediment re-suspended in 300µl molecular grade water. 
This suspension was then boiled at 96oC in a water bath for 15 minutes to lyse and 
inactivate the bacilli. After boiling the suspension was then placed in a sonicating water 
bath for a further 15 minutes. 5µl of this supernatant was used for the amplification 
reaction. 
Preparation of Master Mix: In a sterile room specifically used for preparing master mixes, 
the master mix was prepared by combining the following reagents in a micro tube: 35µl of 
PNM (containing a mixture of triphosphate deoxynucleoside and primers marked with 
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biotin). PNM is included in kit;  5µl of 10X buffer for polymerase incubation; 2.0µl of 2.5mM 
MgCl2; 0.2µl of HotStart Taq polymerase (Qiagen, Germany); 2.0µl of distilled water. The 
final volume was 45µl and this is the amount used for 1 sample. This amount was multiplied 
by the number of samples and controls. After preparation, 45µl amounts of the master mix 
were aliquoted in 0.5ml centrifuge tubes and labeled with the specimen number before the 
addition of DNA. 
Amplification Procedure: In another room and under a BSC, 5µl of each DNA solution was 
added to the respective labeled tube containing the master mix prepared above to reach a 
final volume of 50µl. After addition of the DNA, the tubes were mixed properly by 
vortexing for 10 seconds. Amplification was performed in a thermal cycler (Perkin Elmer 
9600 thermal cycler; Applied Biosystem, CA, USA) using the following amplification 
protocol: one denaturation cycle of 15 min at 95oC, followed by 10 denaturation cycles of 30s 
at 95oC and ten elongation cycles of 2 min at 58oC, followed by 20 additional denaturations 
of 25s at 95oC and annealing of 40s at 53oC, continuing with an elongation step of 40s at 70oC 
and finishing with an extension cycle of 8 minutes at 70oC. After amplification the amplified 
DNA was kept at 4oC until hybridization was done. 
Hybridization and Detection: Hybridization and detection were performed as described by 
the manufacturers using a semi-automated method in a TwinCubator (Hain Lifesciences, 
Nehren, Germany).  
Reverse Hybridization Process: In the Reverse Hybridization process, each strip has a total 
of 17 reaction zones. The first band contains the conjugate control designed to indicate that 
the conjugate has been effectively united with the substrate, thereby facilitating correct 
visualization. The second band includes a universal control designed to detect all known 
mycobacteria and members of the group of gram-positive bacteria with a high G+C content. 
This band is used for checking the presence of the amplified product after hybridization. 
The third band contains a sequence that amplifies a fragment of the 23S rRNA region, which 
is common to all known members of the tuberculosis complex. Amplification bands 4-17 
include probes specific for each of the mycobacteria species. A combination of these bands 
enables identification of the different species of mycobacteria, including M. tuberculosis 
complex.  
Drug susceptibility using MTBDRplus (Line probe assay): This procedure was performed 
exactly as that for identification of mycobacteria except for the difference in the primers 
used and the type of specimen. While cultured material was used for the Common 
Mycobacterium CM assay, clinical specimens were used for the MTBDRplus assay. The 
primers used were specific to detect presence of wild types and mutations. Each strip 
contained bands that detected M. tuberculosis Complex, locus controls (rpoB, katG and inhA) 
as well as Wild Types (WT) and mutations for rpoB, katG and inhA. There were eight WT for 
rpoB gene (WT 1-8) and four mutations (MUT 1, 2A, 2B and 3). For katG gene there was one 
WT and 2 mutations (MUT 1and 2) and for inhA gene 2 WT (1 and 2) and 4 mutations (MUT 
1, 2, 3A and 3B). The isolate was identified as M. tuberculosis complex when the TUB band 
was present. Resistance was determined when a wild type was missing and or a mutation 
present for each of the gene on the strip.  
ELISA test for detection of gamma interferon (IFN-γ): For each ELISA test run, two strips 
or 16 wells were required for standards and 4 wells were required for each patient sample. 
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All reagents except the conjugate were brought to room temperature before the test. For 
each run the required number of strips were removed from the kit and placed on a strip 
holder. The standard dilutions were prepared (8.0IU/ml – 0.125IU/ml) as well as the 
conjugate dilution (5µl conjugate concentrate to 1.0ml of diluent). To each well 50µl 
conjugate dilution was added followed by 50µl standard dilution and 50µl respective patient 
samples. The contents of the wells were mixed for 1-2 minutes using a plate shaker and then 
incubated for 2 hours at room temperature to enable the antigen-conjugate complex to 
adhere to the surface of the microwells. After incubation, the wells were washed with wash 
buffer 5 times using an automated plate washer to remove excess conjugate complex. This 
was followed by the addition of 100µl enzyme substrate (kit component). The wells were 
mixed as before and incubated for a further 30 minutes at room temperature. The reaction 
was stopped after this time with 50µl enzyme stop solution and the optical densities of each 
well measured using wavelengths of 450 and 620. Results were calculated by plotting the 
results on a graph using Microsoft Office Excel. Results greater than 0.35 in the ESAT-6 and 
CFP-10 wells were recorded as positive while results less than 0.35 were recorded as 
negative. 
Data Analysis: Statistical analysis of results of culture, identification, DST as well as 
questionnaire information were performed using Epi Info 3.5.1 version, Centers for Disease 
Control & Prevention software [10] and Open Epi version 2.3 [11]. Associations between 
variables were assessed using Chi-square analysis and Fisher’s exact test. P-values of ≤0.05 
were considered statistically significant. 
Ethical approval: The Ethics committee of the Faculty of Medical Sciences, The University of 
the West Indies, St. Augustine, Trinidad and Tobago, approved the study while written 
permission for use of the specimens was received from the Chief Medical Officers in the 
Ministry of Health from each of the countries represented in the study.  
3. Results 
Specimens and patients: A total of 1,262 specimens comprising 43% culture materials and 
57% clinical samples obtained from 15 Caribbean countries were used for this study. The 
highest number of specimens 28% were obtained from Trinidad & Tobago and the least 
0.2% was from Dominica as depicted on Table 1. For latent TB detection, 560 subjects were 
recruited from Trinidad and Tobago. 
Culture and Identification: The BACTEC 460-TB culture method used for culturing the 
specimens yielded 773 positive cultures and from this, 79.04% (611/773) were identified to 
belong to the Mycobacterium tuberculosis complex group, while 20.96% (162/773) were NTMs 
using NAP test. The Hain Common Mycobacteria (CM) genotyping assay was used to 
further identify the NTMs isolates that consisted of Mycobacterium fortuitium (34.6%), 
followed by Mycobacterium intracellulare (12.3%), Mycobacterium gordonae (6.8%), and 
Mycobacterium kansassi (6.2%). The genotyping assay was unable to identify 16.7% of the 
NTMs, while 7.4% showed characteristics of mixed infection with M. tuberculosis and M. 
fortuitium (referred to Hain Lifesciences for confirmation). The distribution of the NTMs 
isolates from the various Caribbean countries is highlighted in Table 2.  
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St. V&G = St. Vincent and the Grenadines, T&T = Trinidad & Tobago, TCI = Turks & Caicos Islands 
Table 1. Distribution of specimens (clinical samples and cultures) received from fifteen (15) 
Caribbean countries used for this study (%). 
 
N = total number, MTB = Mycobacterium tuberculosis, T&T = Trinidad & Tobago, TCI = Turks and 
Caicos Islands, JAM = Jamaica, SUR = Suriname, GUY = Guyana, MNT = Montserrat, BLZ = Belize, 
NVS = Nevis, BRB = Barbados, ANT = Antigua 
Table 2. Distribution of non tuberculosis mycobacteria (NTM) species identified in 
specimens from Caribbean countries using the Common Mycobacteria (CM) genotyping 
assay 
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3.1 Tuberculin Skin Test and QuantiFERON-TB Gold for the detection of Latent TB 
infection 
A total of 560 subjects were recruited from Trinidad & Tobago for this component of the 
study. They all had blood samples drawn from them and  equally had TST administered on 
their forearm. Of these 560, only 530 of the subjects met the study criteria and were therefore 
included in the final analysis of the results. Summary of the result of the detection of latent 
TB infection using the tuberculin skin test (TST) and the QuantiFERON-TB Gold assay is 
given on Table 3.  
The majority of the subjects were males (73.5%) and between the ages of 40 and 49 years 
(32.8%), The TST results surprisingly revealed that only 1.8% (3/165) of the TB patient 
(control group) readings were <5 mm and only 3% (5/165) were 5-9 mm. As expected, 95.2% 
of the TB patients had a wheal reaction ≥10 mm. None of the HIV subjects had a reaction of 
≥ 10 mm but most of them (90.6%) had a reaction < 5 mm; the rest (9.4%) had a reaction 
measuring 5-9 mm. Among the health care workers, there were no TST readings ≥ 15mm, 
but most (73.2%) were <5 mm. In Trinidad and Tobago, a TST reading ≥ 10 mm among 
uncompromised individuals is considered a positive result. For individuals with HIV or any 
other underlying condition, such as malignancy, the positive cutoff threshold drops to 5-9 
mm. Therefore, the 9.4% of HIV-positive subjects in the current study with readings at that 
level were considered to have positive TST results. Cutoff thresholds for interpretation of 
actual TST results (which are not considered biologically meaningful) range from 5 mm to 
15 mm, depending on the type of high-risk group being surveyed and the level of TB 
prevalence in the study setting. The positive cutoff values used in the current study are 
relatively high but did not affect the final study results due to the clustered distribution of 
the induration values described above. 
The comparative results of the two test methods used for the diagnosis or screening for 
latent TB infection among high risk groups in Trinidad & Tobago (Table 3) revealed that the 
QFT-G assay detected a significantly higher proportion of latent TB infected individuals 
than the TST in all high-risk groups except TB patients (the study controls), among whom 
the TST appeared to be more effective. The differences were statistically significant among 
all target groups studied for each testing method. 
There was no significant age difference between the TST positive subjects and those with 
positive results for the QFT-G assay, who ranged from 20 to 60 years and 21 to 59 years 
respectively (with a mean age of 33.1 versus 34.5 years; p > 0.05). Most of the HIV and TB 
positive subjects (68.8% and 69.7% respectively) were in the 30-59 year age group. 
The average number of hours required to complete the TST was 70.1 hours versus 23.4 hours 
for the QFT-G assay (p <0.0001). The average cost to perform each TST was US $3.70 (for a 
total cost of US $2,065.00), whereas US $18.60 was required to carry out the QFT-G assay 
(total cost of US $10,440.00). These differences were significant (US$3.70 versus US$18.60; p 
=0.0008) and favored use of the TST method for latent TB infection (LTBI) detection. 
When the results of both tests were combined, the rate of LTBI detection increased to 88.7%. 
In the prison inmate group, concomitant results for both tests were available for 62 subjects. 
Of these, 24.2% (15/62) tested positive based on the TST and 56.5% (35/62) tested positive 
based on the QFT-G assay. The rate of concordance between the two tests for this target 
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group was 49.7% (32/62) for negative results, and 15.6% (10/62) for positive results, and 
overall agreement of 76%. For all discordant results, subjects were more likely to be TST-
positive and QFT-G – negative (92.1%) versus TST-negative and QFT-G – positive (7.0%). 
Overall, 39.6% of all subjects had a positive TST result and 51.3% had a positive QFT-G 
assay result. The significant differences obtained for TAT favored the QFT-G assay, whereas 
the cost of material required to perform the tests favored the TST. 
 
N = total number of subjects tested. a Individuals who came into contact with active TB patients - 
friends and family members. b In 2010 US dollars ($1 = 6.35 TTD). c Average number of hours from time 
of intradermal injection of tuberculin on subjects’ forearms to the time wheal reaction at puncture was 
read within 72 hours. 
Table 3. Comparison of QuantiFERON® TB-Gold (QFT-G) assay and tuberculin skin test 
(TST) in diagnosis/screening for latent tuberculosis (TB) infection among high-risk groups 
from Trinidad & Tobago 
The average number of hours required to complete the TST was 70.0 hours versus 23.0 hours 
for the QFT-G assay (p <0.0001). The average cost to perform each TST was US $3.70 (for a 
total cost of US $2,065.00), whereas US $18.60 was required to carry out the QFT-G assay 
(total cost of US $10,440.00). These differences were significant (US$3.70 versus US$18.60; p 
=0.0008) and favored use of the TST method for LTBI detection. 
Drug Susceptibility Testing (DST): The BACTEC 460 TB System was used to successfully 
determine the drug susceptibility tests (DST) of 91.3% (558/611) cultures identified as M. 
tuberculosis Complex from 12 of the Caribbean countries as revealed on Table 4. Overall, a 
total of 42 (7.5%) isolates from 8 countries showed resistance to at least one or more anti-TB 
drugs.  
Analysis of the susceptibility pattern to the anti TB agents revealed that 73.8% (31/42) of 
the isolates were resistant to isoniazid (INH), 66.7% (28/42) were resistant to rifampicin 
(RIF), 38.9 (16/42) were resistant to both RIF and INH while 28.6% (12/42) were either 
resistant to streptomycin or ethambutol. The highest number of isolates subjected to DST 
analysis were obtained from Trinidad & Tobago and then followed by Guyana. Although 
no multidrug resistance was seen in isolates from several of the Caribbean countries,  the 
highest frequency of resistance and multidrug resistance were noted among isolates from 
Guyana. 
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The Hain Genotyping line probe assay (MTBDRplus) was further used to genotypically 
analyze a total of 33 isolates that had initially been identified to be resistant to INH (26 
isolates) and/or RIF (24 isolates) by the phenotypic method. This result is shown on Table 5. 
Overall, of the 24 isolates showing resistance to RIF using the phenotypic method, 23 
(95.8%) showed resistance with the genotypic method. Of the 26 isolates showing resistance 
to INH with the phenotypic method, 9 (34.6%) showed resistance with the genotypic 
method. Additionally, 2 isolates sensitive to INH with the phenotypic method showed 
resistance with the genotypic method and 1 isolate resistant to RIF with the phenotypic 
method was sensitive with the genotypic method. 
Resistance to RIF was identified genotypically by the presence or absence of mutations in 
the rpoB gene, while resistance to INH was identified by the presence or absence of 
mutations in the katG and inhA genes. The codons most frequently involved in RIF 
mutations were S-531L (57.1%) and codon S-516L (20%). Twenty (20) isolates carried the 
most common mutation, Ser531 → Leu. As for INH resistance, of the 9 isolates that the 
Genotype MTBDRplus detected, 78% of them carried mutation at S315T1 codon of the katG 
gene, showing AGC  →  ACC mutation, and 22% showed AGC  →  ACA mutation. Equally, 
64.7% of these mutation occurred at these bands at the inhA gene in the MDR isolates from 
the region. 
 
N = number of isolates tested, S = isolates fully susceptibile to all first line drugs, R = isolates resistant to 
any of the first line drugs, MDR = isolates resistant to both isoniazid and rifampcin, T&T – Trinidad and 
Tobago, TCI – Turks and Caicos Islands, St. V&G – St. Vincent and the Grenadines. 
Table 4. BACTEC 460 TB System susceptibility results of 558 TB isolates (patients) from the 
Caribbean (%) 
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MWT = Missing wild type, MUT = mutation, N = none, R = resistant, S = susceptible, R-IRE = resistant 
to isoniazid, rifampicin and Ethambutol, R-SIRE = resistant to Streptomycin, isoniazid, rifampicin and 
ethambutol 
Table 5. Results of MTBDRplus for isolates that showed resistance to INH and RIF using 
BACTEC 460 assay 
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4. Discussions 
One of the major objectives of this study was to evaluate the tuberculin skin test (TST), the 
method currently being used in Trinidad & Tobago, with that of the Quantiferon TB-Gold 
Test (a new IFN-Ǆ based test that has now been introduced in the market for LTBI 
detection) to determine the cost and efficiency of these methods in detecting latent TB 
infection (LTBI). Unlike the TST and IFN-Ǆ analysis, most diagnostic assays for detecting 
M. tuberculosis infection are based on either isolation or identification of the bacteria, 
which makes them inapplicable for diagnosis of latent infection. The development of IFN-
Ǆ tests to detect T-cells specific for M. tuberculosis antigens addressed this important issue. 
The current study was carried out among individuals from various groups with a high 
risk of developing TB due to either exposure to or contact with TB patients, lack of 
isolation facilities, or weak infection control. In the current study, the two selected testing 
methods (QFT-G and TST) detected LTBI among the various target groups at different 
rates. 
Among the TB patient [control] group, the rate of TB detection by the QFT-G assay (70.2%) 
was significantly different from that of the TST. This rate of detection was similar to that 
observed by Lee et al., who reported a sensitivity of 70% among 87 patients diagnosed with 
TB [12], and higher than both the 64.4% rate of detection observed by Kobashi et al. in Japan 
[13] and the rate observed by Dewan et al., who reported a sensitivity of 60% in culture-
confirmed cases [14]. However, the 70.2% rate was lower than that reported by both Kang et 
al. (81% sensitivity in 54 patients) and Mori et al. (89% sensitivity among 118 patients) [15, 
16]. More recently, Kobashi et al. demonstrated significant differences in the quantitative 
responses of IFN-Ǆ to M. tuberculosis between patients with active TB disease and those with 
LTBI [13].  
Combining the results for the QFT-G assay and the TST in the current study increased the 
overall sensitivity for detection of LBTI among the culture-confirmed TB-infected control 
group. This confirms and reinforces recommendations that negative results should not be 
used alone to exclude active TB but should be interpreted in conjunction with other clinical 
and diagnostic findings [17]. It also underscores the fact that the QFT-G assay has a limited 
role in the evaluation of patients with culture-confirmed TB. The authors of the current 
study agree with Kobashi et al.’s conclusion that it would be difficult to use the QFT-G assay 
to completely discriminate active TB disease from LTBI [13].  
In the current study, 43.3% of all HIV patients included in the analysis had a positive result 
for the QFT-G assay. This was in huge contrast to the earlier study by Kobashi et al. [13], in 
which all HIV patients produced QFT-G–positive results. The indeterminate or nonreactive 
results observed in some of the HIV-positive subjects in the current study also contrast with 
those found by Ferrara et al. [17]. In the current study, the QFT-G assays were run several 
times to minimize the effect of laboratory and procedural errors. However, the 
indeterminate and nonreactive results persisted, with test results continuing to produce low 
mitogen levels. Although all indeterminate or nonreactive results were excluded from the 
final analysis, the QFT-G assay results should be interpreted with caution, bearing in mind 
the high prevalence of HIV in Trinidad & Tobago and the Caribbean region. Several possible 
explanations for a high rate of indeterminate and nonreactive results have been adduced 
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and these include the presence of lymphocytopenia and/or inflammatory and 
immunosuppressive conditions, as well as hypoalbuminemia, which suggests poor 
nutritional status [13], and there is a high probability that some of these conditions could 
have existed among the subjects of the current study. Lymphocytopenia (especially the CD4 
strain) has been shown to depend on the elaboration of inflammatory cytokines by T-cells 
previously sensitized to M. tuberculosis–specific antigens in QFT-G assays. In the blood, 
mononuclear cells from peripheral blood are stimulated in vitro, and the production of IFN-
Ǆ from sensitized T-lymphocytes by M. tuberculosis–specific antigen is measured by ELISA 
in the QFT-G [18,19]. 
In the current study, however, only 58% of TST-positive subjects had a positive QFT-G 
result. More than half of this group consisted of prison inmates with a documented TST > 10 
mm. In Trinidad & Tobago, TST is likely to be a very good indicator of latent infection in 
recently exposed individuals because of the following reasons (a) most individuals under 
the age of 20 years did not receive the BCG vaccination, which was discontinued during the 
early 1990s, and (b) BCG vaccination has been observed to significantly increase the 
likelihood of a positive TST in subjects without LTBI. 
Multiple outbreaks of TB, including those involving the multi-drug-resistant strain (MDR-
TB), have been reported in prisons and jails, especially among HIV-infected inmates, a 
population regarded as having moderate risk of acquiring TB [20]. The results of the 
current study from this moderate-risk population show that prevalence of LTBI was 24.2% 
and 56.5% based on the TST and the QFT-G assay respectively. These values were quite 
high compared to those observed in correctional facilities in the United States, where 
prevalence was less than 10%. However, the QFT-G values obtained in the current study 
were in line with the current rate of TB in Trinidad & Tobago, which is estimated to be 
about 17 per 100 000 population [21]. It has been suggested that annual TB screening of 
prison inmates using the TST may account for the increase in the number of TST-positive 
results, due to the “boosting” effect caused by repeat use of the test. However, this type of 
screening is not carried out among prison inmates in Trinidad & Tobago. Therefore, the 
high rate of TST-positive results in the current study could be attributed mainly to 
exposure to the disease. 
The prevalence of LTBI among health care workers using the TST in the current study was a 
mere 7.5%. This value was very low compared to those reported by studies in Portugal 
(33%) and Germany (10%)[22, 23]. The low value found in the current study may have been 
due to a smaller sample size and the use of a higher positive cutoff. Like the studies in 
Portugal and Germany, the current study showed that the QFT-G assay was more useful 
than the TST in identifying LTBI among health care workers. As this target group may be 
exposed to TB more frequently than the local population, screening of staff exposed to the 
disease is frequently recommended to identify infected individuals and treat them 
adequately and promptly. Because the QFT-G assay was more sensitive than the TST in 
detecting LTBI, the authors of the current study strongly support its use in screening health 
care workers in Trinidad & Tobago. 
The TST may also be less desirable due to complications in interpreting its results caused by 
the above-mentioned boosting effect (from repeat testing) as well as conversions and 
reversions (changes in results from negative at baseline to positive and vice versa, 
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respectively). In a study on health care workers in India, Pai et al. suggested that individuals 
with recent exposure to TB usually presented with large increases (≥ 10 mm) in TST 
indurations that were always accompanied by substantial increases in IFN-Ǆ [24]. This 
finding was in line with the results of the current study. 
The QFT-G assay also fared better than the TST in terms of TAT. In terms of cost, 
however, the TST appears best suited for the resource-strapped environment of Trinidad 
& Tobago (if the calculation of this variable is based mainly on the cost of the materials 
required to perform the test versus the cost of labor and other inputs). This argument is 
partly supported by Pooran et al., who concluded in a recent report that screening for 
LTBI using TST alone was the most cost-effective testing strategy but ultimately incurred 
the highest cost due to test inaccuracies [25]. Another factor that may make the TST less 
cost-effective over time is high replacement costs, since the Mantoux test solution is often 
not accessible in developing countries and would have to be replaced with the relatively 
labor-intensive IFN-Ǆ release assay. Minimizing cost for TB testing has become 
increasingly important because prevalence of the disease has fallen dramatically in 
developed countries and more than 90% of all cases worldwide occur in resource-
strapped developing countries [26]. However, as pointed out by both Diel et al. and Marra 
et al., use of the IFN-Ǆ release assay alone or in combination with the TST for screening 
close TB contacts prior to LTBI treatment is highly cost-effective in reducing the TB 
disease burden [27, 28, 29].  
4.1 Profiles of drug susceptibility patterns of Mycobacterium tuberculosis isolates 
encountered in the Caribbean 
Drug resistance using the Hain Lifescience MTBDRplus line probe assay revealed that this 
method performed very well for the detection of RIF resistance isolates in the region. This 
is in agreement with the high sensitivity reported elsewhere [30, 31, 32]. However, the 
results for detection of resistance to INH were much lower using this assay. This 
observation is not unique since the molecular mechanisms for INH resistance are not fully 
understood and about 25-30% of phenotypic INH-resistance associated mutations are still 
unaccounted for [32].  
This study revealed that the codon most frequently involved in the mutation was the S-531L 
of the rpoB gene among the RIF resistant isolates. Similar result has been reported by 
Cavusoglu et al., 2007 [34], but Barnard et al., 2008 [35], reported that most mutations in the 
isolates tested in their study occurred at several other codons. Also, a high proportion of the 
mutational changes were detected in the S-315T1 codon of the katG gene for the INH and 
RIF monoresistant isolates in this study in contrast to regions reported elsewhere [35]. This 
was a trend reported in a high burden setting that seem to be a different trend among the M. 
tuberculosis isolates seen here in the Caribbean region.  
The MTBDRplus genotype assay allowed for the rapid and specific detection of most 
mutations conferring resistance to RIF and to a lesser extent INH. Collective observations 
have indicated that mutations to the rpoB gene may account for the greater than 96% of the 
resistance to RIF [30,35]. This present study indicated that this is also true for Caribbean TB 
isolates that showed an overall resistance detection of 95.8% with the MTBDRplus assay.  
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Detection of INH resistance using the MTBDRplus assay for the katG and inhA gene was 
disappointing. In this study, only 34.6% resistance to INH was detected using the 
MTBDRplus assay which is less than that reported by Johnson et al., 2008 [36]. Other 
studies showed detection of 60-90% within the katG gene and 15-43% within the inhA 
gene [32, 31]. Nonetheless, it must be kept in mind that the isolates used in this study 
were screened using the single drug concentration of 0.1μg/ml of INH in the BACTEC 460 
TB system (which detects low levels of resistance to INH at this concentration, mainly 
useful for therapeutic purposes). The study did not discriminate between strains with low 
levels of INH resistance with those harboring a high level of resistance, a fact that may 
indirectly explain the poor agreement between the number of INH-resistant isolates 
detected using the gold-standard BACTEC 460 TB as compared to the MTBDRplus (26 
instead of 9). In fact, it has been shown that the MTBDRplus assay was unable to detect 
low levels of INH resistance that was commonly detected using the BACTEC 460 TB 
system [32].  
Previous reports have confirmed that high INH concentration levels of more than 
0.4µg/ml can be detected in the katG genes among M. tuberculosis isolates that are 
resistant to the drug [32]. This detection of low INH resistance among the M. tuberculosis 
isolates seen in this study could perhaps be because of the low concentration of the INH 
drug used. In addition, the MTBDRplus assay only detects those resistances of M. 
tuberculosis that have their origins in the rpoB, katG and inhA regions (MTBDRplus kit 
insert). Since resistance originating from mutations of other genes or gene regions as well 
as other RIF and INH mechanisms are not detected by the MTBDRplus, it could be that 
other mechanisms of resistance possessed by the isolates from the Caribbean were not 
detected. This will definitely require further studies since such was outside the scope of 
this study.  
With the MTBDRplus assay, clinical specimens that are AFB positive with moderate to many 
AFBs, can be reliably tested for drug resistance. Furthermore, the genotypic DST method 
was able to detect drug resistance in samples that were contaminated as well as in those that 
had lost viability, circumventing the need to request follow-up sputum thus decreasing the 
time between specimen collection, results and treatment of the patient. This study also 
showed that less time was spent using the MTBDRplus in detecting INH and RIF resistance 
in TB isolates in the Caribbean. Using the BACTEC 460 TB system, the mean time for 
reporting results showing any drug-resistance was 32 days for cultures and 40 days for 
clinical specimens. This time represented repeating all drug-sensitivities for specimens 
showing any resistance. For specimens that were sensitive to anti-TB drugs, the mean time 
was 21 days for clinical specimens and 14 days for isolates. 
Determination of drug resistance is difficult due to technical reasons and in several cases; 
these results are not always accurate [37]. In addition, it can take up to 6 weeks to get a 
phenotypic DST result and during this time many transmission events may take place. 
Therefore, alternative methods need to be evaluated to improve the speed of diagnosis 
especially drug resistant TB and this is what was achieved using the MTBDRplus assay in 
this study. With the BACTEC 460 system, culture material was not able to give results for 
non viable or contaminated materials; however in this study the MTBDRplus system gave 
identifiable results. This is in agreement with what has been reported as these tests are able 
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to perform on specimens that contain non viable bacilli or from specimen that were 
contaminated by other bacteria and fungi [32, 35, 36]. 
Although MTBDRplus assay has limitations as with any DNA-based screening nucleic acid 
sequence, it is possible that mutations that do not cause an amino acid exchange (silent 
mutations) will still produce the absence of one of the wild type probes. In addition, this 
assay only detects those resistance of the M. tuberculosis that have origins in the rpoB, katG 
and inhA regions, yet the high sensitivity of RIF resistance detection is a plus point since this 
test can be used for detecting RIF resistance, a surrogate marker for multiple drug resistance 
in M. tuberculosis isolates. This assay is an excellent test to use on selected clinical samples 
because the amount of time required in generating a result was within 24 hours after receipt 
of specimen, culturing of the specimen is not required and contaminated as well as non-
viable cultures can be used. Finally, the test method was also cheaper to use in resource-
poor countries like in the Caribbean region. 
Despite the global expansion in coverage of drug-resistance surveillance, data on drug 
resistance are still unavailable for more than 100 countries throughout the world [38]. Even 
in the Caribbean there is a paucity of information or data on the anti TB susceptibility 
pattern. This study was very important as it provided data on drug resistance that was 
lacking for most of the countries in the Caribbean. The level of drug resistance observed in 
most of the countries in this study was quite low with the exception of Guyana. Although 
drug resistance has been reported from several countries in the Caribbean, data reported to 
WHO on drug resistance is lacking as only Trinidad and Tobago reported 1 case of MDR-TB 
to the WHO in 2006 [39].  
In this study, resistance to anti-TB medications was seen in seven countries, five of which 
had >5 cases of TB/100,000 population and with one country (Guyana) accounting for 85% 
of the MDR-TB strains seen. This data confirms the continued existence of drug resistance in 
Guyana, as an earlier report by Menner et al., 2005 [40] also reported a high frequency of 
drug resistance in this country with 22.2% of the isolates tested showing resistance to at least 
one anti-tuberculosis drug and 11.1% showing resistance to INH and RIF [40]. The reason 
for the continued persistence of MDR-TB in Guyana according to Menner et al is the lack of 
human resources to adequately follow up and monitor patient treatment as well as poor 
management of the tuberculosis control programme [40]. In this present study similar 
results were seen as 20.5% of isolates tested showed resistance to at least one anti-TB drug 
and 14.5% showed resistance to INH and RIF (MDR-TB).  
Unlike previous studies from Africa, Haiti and Guyana that showed high levels of drug-
resistance with high TB/HIV co-infection rates [40, 41, 42, 43, 44], the moderate TB incidence 
seen in the rest of the Caribbean was not accompanied by any substantial level of drug-
resistance. For example, there was no case of drug resistance among TB isolates from 
Trinidad and Tobago. This was very surprising especially with the high levels of TB/HIV 
co-infection (30.6% of the TB positive cases) and the high defaulter rate (22.7% of the TB 
positive cases). As reported in the literature, drug resistance was commonly seen in other 
countries where there was inadequate chemotherapy and also where HIV co-infections was 
present [45, 46]; but this is in contrast to Trinidad & Tobago where despite the high 
prevalence of HIV co-infection with TB, drug resistant cases were almost non- existent. 
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The absence of drug resistance in Trinidad and Tobago may be attributed to the excellent 
care and treatment TB programme such as direct observed treatment (DOT), adequate 
provision and supply of TB drugs that exists in the country. Additionally, all patients with 
tuberculosis are admitted and managed at the Caura Chest hospital until they become non-
infectious, after which they are monitored on a regular basis by public health officials from 
the TB programme. 
In Suriname drug resistance was rarely seen and when it occurred, only mono-resistance 
was seen. Mono-resistance was also recorded for isolates from Jamaica and The Bahamas, 
two countries where HIV infection is also relatively high and where low levels of 
resistance are seen. As in Trinidad and Tobago, the TB programmes in these countries are 
well managed and there is a very good collaboration between the TB and the HIV 
programmes.  
A review of the literature for drug resistance in other parts of the Caribbean showed that 
similar low levels of drug resistance have been seen in the French Caribbean Islands of 
Guadeloupe and Martinique where there is significant migrant population from Haiti, an 
area of high drug resistance. The incidence of monoresistance in the French Caribbean 
Islands was 12.9%, however the incidence of MDR-TB was much lower with a rate of 0.9% 
[47].  
Limitations of the study: An inherent limitation designed to compare cost and turnround 
time against an imperfect conventional test such as TST is that no gold standard has been 
established for resolution of discordant results. The MTBDRplus assay has the limitation 
that as a DNA assay based procedure that screens for nucleic acid sequence and not 
amino acid sequence, it is possible that mutations that do not cause amino acid exchange 
(silent mutations) will result in the absence of one of the wild types probes. Besides the 
assay detects only resistance that originate in the rpoB, katG and inhA regions of the 
Mycobacterium tuberculosis. Hence other regions where resistance occurs will completely 
be missed.  
The lack of adequate facilities for manipulation of solid and liquid cultures of M. tuberculosis 
is a major challenge in the Caribbean. Because of this drug susceptibility testing information 
for proper management of patients infected with TB as well as identification of species is 
limited. 
5. Conclusions 
Despite the several constraints and limitations, this study demonstrated that the QFT-G test 
was more effective and a quicker turnaround time was achieved over the TST in detecting 
LTBI among several target groups in the population studied. However, because the QFT-G 
appears more costly as well as showing indeterminate and non reactive response for 
immuno-compromised subjects such as HIV positive patients, care must be taken when 
screening or making a diagnosis of LTBI based on QFT-G results in a poor resource and high 
HIV prevalence setting like Trinidad & Tobago or any other Caribbean country. 
The turnaround time for results for line probe assays is also a major asset. Additionally, the 
identification of organisms and DST can be performed on contaminated as well as non-
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viable specimens. Finally, the cost of this assay makes it ideal for use as it is less than 2 times 
that of traditional culture methods. 
Although the Quantiferon Gold TB test results were comparable in many aspects with other 
published international studies the use of this test for the Caribbean may still be limited due 
to the cost involved when compared to the Tuberculin Skin Test. This is so because of the 
cost of the kit, transportation issues and the laboratory component of the test.  
6. Recommendations 
The authors therefore support the recommendation that Quantiferon Gold TB test be used 
in conjunction with the well established TST for the screening of patients suspected of 
infection. Confirmation of positive TST can then be performed using the QFT-G test if 
warranted. In cases where the patient is co-infected with HIV, the interpretation of the test 
should be made in collaboration with the CD4+ count of the patient as this test is 
dependent on the reaction of T-cells and if the CD4 count is low then the result can be 
falsely negative. 
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